Supernus Pharmaceuticals, Inc.
$42.00
-$0.92 (-2.14%)
$41.60Day Range$42.89
Key Statistics
Market Cap
$2.45B
Shares Outstanding
58.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 1, 2012
Round Lot
100
Locale
US
Trading Data
Day Open
$42.89
Day High
$42.89
Day Low
$41.60
Volume
1.18M
VWAP
$42.01
Prev Close
$42.92
Transactions
--
Acc. Volume
--
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
PHARMACEUTICAL PREPARATIONSSIC 2834778 employees9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850301-838-2500IPO May 1, 2012US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001356576
- Composite FIGI
- BBG000BP0HX7
- Share Class FIGI
- BBG001SFKFF1
- Ticker Root
- SUPN
- SIC Code
- 2834
About Supernus Pharmaceuticals, Inc. (SUPN) Stock
Supernus Pharmaceuticals, Inc. (SUPN) closed the 2026-09-18 session at $42.00, down 2.14% versus the previous close (-0.92). The stock opened at $42.89 and traded between $41.60 and $42.89 during that session. Session trading volume was 1.2M shares. The volume-weighted average price (VWAP) is $42.01.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Supernus Pharmaceuticals, Inc. has a market capitalization of $2.45 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. SUPN is listed on the XNAS exchange. The company employs approximately 778 people. Supernus Pharmaceuticals, Inc. is headquartered in ROCKVILLE, MD. The recorded listing date is 2012-05-01.
On this page you can find market SUPN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.